GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Respiratorius AB (XSAT:RESP) » Definitions » PS Ratio

Respiratorius AB (XSAT:RESP) PS Ratio : 365.88 (As of Apr. 22, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Respiratorius AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Respiratorius AB's share price is kr6.22. Respiratorius AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.02. Hence, Respiratorius AB's PS Ratio for today is 365.88.

The historical rank and industry rank for Respiratorius AB's PS Ratio or its related term are showing as below:

XSAT:RESP' s PS Ratio Range Over the Past 10 Years
Min: 50.7   Med: 197.18   Max: 608.82
Current: 365.88

During the past 13 years, Respiratorius AB's highest PS Ratio was 608.82. The lowest was 50.70. And the median was 197.18.

XSAT:RESP's PS Ratio is ranked worse than
93.73% of 973 companies
in the Biotechnology industry
Industry Median: 8.15 vs XSAT:RESP: 365.88

Respiratorius AB's Revenue per Sharefor the three months ended in Dec. 2024 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.02.

Back to Basics: PS Ratio


Respiratorius AB PS Ratio Historical Data

The historical data trend for Respiratorius AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Respiratorius AB PS Ratio Chart

Respiratorius AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Respiratorius AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 148.59 655.88 441.18 -

Competitive Comparison of Respiratorius AB's PS Ratio

For the Biotechnology subindustry, Respiratorius AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Respiratorius AB's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Respiratorius AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Respiratorius AB's PS Ratio falls into.


;
;

Respiratorius AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Respiratorius AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=6.22/0.017
=365.88

Respiratorius AB's Share Price of today is kr6.22.
Respiratorius AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Respiratorius AB  (XSAT:RESP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Respiratorius AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Respiratorius AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Respiratorius AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.

Respiratorius AB Headlines

No Headlines